Innoviva, Inc. (INVA) Dividend History

Innoviva, Inc. is a biotechnology company focused on the development and commercialization of respiratory and other specialty healthcare products. It primarily licenses its portfolio of pharmaceutical products and intellectual property to partner companies, with a strong emphasis on inhaled therapeutics for conditions like asthma and COPD. The company leverages its expertise in respiratory medicine to generate royalty revenue and support its strategic growth initiatives.

1350 Old Bayshore Highway, Burlingame, CA, 94010
Phone: (650) 238-9600
Website: https://www.inva.com
Dividend Yield: 4.88%
Dividend Frequency: Quarterly

Dividend History

Pay Date Amount Ex Dividend Date Record Date
September 30, 2015 $0.25 09/08/2015 09/10/2015
June 30, 2015 $0.25 06/10/2015 06/12/2015
March 31, 2015 $0.25 03/10/2015 03/12/2015
December 23, 2014 $0.25 11/21/2014 11/25/2014
September 18, 2014 $0.25 08/26/2014 08/28/2014

Dividends Summary

  • Innoviva, Inc. has issued 5 dividends over a period of about a year
  • The most recent dividend was paid 3629 days ago, on September 30, 2015
  • The first recorded dividend was paid on September 18, 2014
  • The highest dividend payout was $0.25 per share
  • The average dividend over this 1 year span is $0.25 per share

Company News

  • Innoviva (INVA) Q2 Sales Jump 64%

    Innoviva reported Q2 2025 earnings with $0.77 EPS and $100.3 million revenue, exceeding analyst expectations. Specialty therapeutics sales increased 54% year-over-year, driven by new product launches like GIAPREZA and ZEVTERA, while operating income declined due to increased R&D expenses.

    The Motley Fool
    Featured Companies: ARMP
  • Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

    Basilea Pharmaceutica Ltd has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc. for the commercialization of Basilea's hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States.

    GlobeNewswire Inc.
  • Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

    Cantor Fitzgerald has initiated coverage on Innoviva, Inc. (NASDAQ:INVA), citing the company’s unique business model centered around royalties and healthcare assets. The company receives royalties from GSK plc (NYSE:GSK) for popular asthma and COPD products, including Relvar/Breo and Anoro, with combined sales of over $2 billion in 2023. “We believe their manufacturing complexity provides further protection from potential competitors,” Cantor analyst writes. Cantor projects around $1.1 billion of 5-year projected royalty revenues from GSK and initiates Innoviva with an Overweight rating. The analyst says Breo and Anoro have exceeded expectations, even during challenging times such as the COVID-19 ...Full story available on Benzinga.com

    Benzinga
  • 10 stocks you can bet on being inflation-proof

    High-quality stocks can do well when prices are rising or falling. Here’s why.

    MarketWatch
    Featured Companies: AM CW CXW HCC OTTR PCAR RDN SLM TNC
  • J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises

    J&J (JNJ) beats estimates for first-quarter earnings and sales. It raises full-year sales and earnings guidance.

    Zacks Investment Research
    Featured Companies: JNJ
Page data last updated 09/05/2025 22:13:58 UTC Dividend yield is calculated using only dividends that have already been paid. Future or declared dividends are not included